Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency
Conditions
Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes, Cystic Fibrosis
Trial Timeline
Aug 1, 2008 → Feb 1, 2009
NCT ID
NCT00662675About Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21
Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 is a phase 3 stage product being developed by Johnson & Johnson for Exocrine Pancreatic Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00662675. Target conditions include Exocrine Pancreatic Insufficiency, Steatorrhea, Malabsorption Syndromes.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00662675 | Phase 3 | Completed |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 33 |
| CREON | AbbVie | Approved | 85 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 52 |
| Pancrelipase + Placebo | AbbVie | Approved | 85 |
| Pancrelipase Capsules | AbbVie | Approved | 85 |
| Lipacreon | Viatris | Pre-clinical | 20 |